基于mTOR自噬途径宿主导向疗法在抗结核分枝杆菌感染中的研究进展  

Progress of host-directed therapy based on mTOR autophagy pathway in anti-mycobacterium tuberculosis infection

作　　者：吴金凤 许瑞[1] 杜先智[1] Wu Jinfeng;Xu Rui;Du Xianzhi(Department of Respiratory Medicine,the Second Affiliated Hospital of Chongqing Medical University,Chongqing 400000,China)

机构地区：[1]重庆医科大学附属第二医院呼吸内科,重庆400000

出　　处：《国际呼吸杂志》2022年第13期984-988,共5页International Journal of Respiration

基　　金：重庆市自然科学基金(cstc2021jcyj-msxmX0216)。

摘　　要：由于耐多药或耐利福平结核菌株的出现,研究新型结核治疗方案成为必要。宿主抗结核分枝杆菌(MTB)感染主要依靠细胞免疫实现的,自噬是一种宿主防御的基本途径,哺乳动物雷帕霉素靶蛋白(mTOR)是自噬的主要调节剂,与控制MTB的负荷有关。近年来,研究表明一些药物或小分子物质通过mTOR途径激活自噬的宿主导向疗法可实现减轻宿主体内MTB负荷。故本文就基于mTOR途径宿主导向疗法在抗MTB感染中的研究进展作相应的阐述。The emergence of multi-drug resistant or rifampin-resistant Mycobacterium tuberculosis(MTB)has highlighted the necessity to develop novel therapeutics.The host′s resistance to MTB infection is mainly achieved by cellular immunity.Autophagy is a basic pathway of host defense,regulated by the mammalian target of rapamycin(mTOR),has been associated with the control of the MTB load.In recent years,study shows that host-directed therapies activate autophagy by some drugs or small molecules through the mTOR pathway can reduce MTB load in the host.In this review,the progress of host-directed therapy is discussed based on mTOR pathway against MTB infection.

关 键 词：结核分枝杆菌 结核 肺 自噬 宿主定向治疗 

分 类 号：R52[医药卫生—内科学]